Defective hCNT1 transport contributes to gemcitabine chemoresistance in ovarian cancer subtypes

Overcoming transport defects using a nanoparticle approach

Sau Wai Hung, Sean Marrache, Shannon Cummins, Yangzom D. Bhutia, Hardik Mody, Shelley B. Hooks, Shanta Dhar, Rajgopal Govindarajan

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Nucleoside analogs are used as chemotherapeutic options for the treatment of platinum-resistant ovarian cancers. Human concentrative nucleoside transporter 1 (hCNT1) is implicated in sensitizing solid tumors to nucleoside analogs although its role in determining drug efficacy in ovarian cancers remains unclear. Here we examined the functional expression of hCNT1 and compared its contributions toward gemcitabine efficacy in histological subtypes of ovarian cancer. Radioactivity analysis identified hCNT1-mediated 3H-gemcitabine transport in ovarian cancer cells to be significantly reduced compared with that of normal ovarian surface epithelial cells. Biochemical and immunocytochemical analysis identified that unlike normal ovarian cells which expressed high levels of hCNT1 at the apical cell surface, the transporter was either diminished in expression and/or mislocalized in cell lines of various subtypes of ovarian cancer. Retroviral expression of hCNT1 selectively rescued gemcitabine transport in cell lines representing serous, teratocarcinoma, and endometrioid subtypes, but not clear cell carcinoma (CCC). In addition, exogenous hCNT1 predominantly accumulated in intracytoplasmic vesicles in CCC suggesting defective cellular trafficking of hCNT1 as a contributing factor to transport deficiency. Despite diminution of hCNT1 transport in the majority of ovarian cancers and apparent trafficking defects with CCC, the chemotherapeutic efficacy of gemcitabine was broadly enhanced in all subtypes when delivered via engineered nanoparticles (NPs). Additionally, by bypassing the transport requirement, the delivery of a gemcitabine-cisplatin combination in NP formulation increased their synergistic interactions. These findings uncover hCNT1 as a putative determinant for nucleoside analog chemoresistance in ovarian cancer and may help rationalize drug selection and delivery strategies for various histological subtypes of ovarian cancer.

Original languageEnglish (US)
Pages (from-to)233-240
Number of pages8
JournalCancer Letters
Volume359
Issue number2
DOIs
StatePublished - Jan 1 2015
Externally publishedYes

Fingerprint

gemcitabine
Nucleoside Transport Proteins
Ovarian Neoplasms
Nanoparticles
Nucleosides
Carcinoma
Human Trafficking
Teratocarcinoma
Cell Line
Platinum
Pharmaceutical Preparations

Keywords

  • Chemoresistance
  • Gemcitabine
  • HCNT1
  • Nanoparticles
  • Nucleoside transporter
  • Ovarian cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Defective hCNT1 transport contributes to gemcitabine chemoresistance in ovarian cancer subtypes : Overcoming transport defects using a nanoparticle approach. / Hung, Sau Wai; Marrache, Sean; Cummins, Shannon; Bhutia, Yangzom D.; Mody, Hardik; Hooks, Shelley B.; Dhar, Shanta; Govindarajan, Rajgopal.

In: Cancer Letters, Vol. 359, No. 2, 01.01.2015, p. 233-240.

Research output: Contribution to journalArticle

Hung, Sau Wai ; Marrache, Sean ; Cummins, Shannon ; Bhutia, Yangzom D. ; Mody, Hardik ; Hooks, Shelley B. ; Dhar, Shanta ; Govindarajan, Rajgopal. / Defective hCNT1 transport contributes to gemcitabine chemoresistance in ovarian cancer subtypes : Overcoming transport defects using a nanoparticle approach. In: Cancer Letters. 2015 ; Vol. 359, No. 2. pp. 233-240.
@article{9ff97f5266c7434b88ea45f28509089b,
title = "Defective hCNT1 transport contributes to gemcitabine chemoresistance in ovarian cancer subtypes: Overcoming transport defects using a nanoparticle approach",
abstract = "Nucleoside analogs are used as chemotherapeutic options for the treatment of platinum-resistant ovarian cancers. Human concentrative nucleoside transporter 1 (hCNT1) is implicated in sensitizing solid tumors to nucleoside analogs although its role in determining drug efficacy in ovarian cancers remains unclear. Here we examined the functional expression of hCNT1 and compared its contributions toward gemcitabine efficacy in histological subtypes of ovarian cancer. Radioactivity analysis identified hCNT1-mediated 3H-gemcitabine transport in ovarian cancer cells to be significantly reduced compared with that of normal ovarian surface epithelial cells. Biochemical and immunocytochemical analysis identified that unlike normal ovarian cells which expressed high levels of hCNT1 at the apical cell surface, the transporter was either diminished in expression and/or mislocalized in cell lines of various subtypes of ovarian cancer. Retroviral expression of hCNT1 selectively rescued gemcitabine transport in cell lines representing serous, teratocarcinoma, and endometrioid subtypes, but not clear cell carcinoma (CCC). In addition, exogenous hCNT1 predominantly accumulated in intracytoplasmic vesicles in CCC suggesting defective cellular trafficking of hCNT1 as a contributing factor to transport deficiency. Despite diminution of hCNT1 transport in the majority of ovarian cancers and apparent trafficking defects with CCC, the chemotherapeutic efficacy of gemcitabine was broadly enhanced in all subtypes when delivered via engineered nanoparticles (NPs). Additionally, by bypassing the transport requirement, the delivery of a gemcitabine-cisplatin combination in NP formulation increased their synergistic interactions. These findings uncover hCNT1 as a putative determinant for nucleoside analog chemoresistance in ovarian cancer and may help rationalize drug selection and delivery strategies for various histological subtypes of ovarian cancer.",
keywords = "Chemoresistance, Gemcitabine, HCNT1, Nanoparticles, Nucleoside transporter, Ovarian cancer",
author = "Hung, {Sau Wai} and Sean Marrache and Shannon Cummins and Bhutia, {Yangzom D.} and Hardik Mody and Hooks, {Shelley B.} and Shanta Dhar and Rajgopal Govindarajan",
year = "2015",
month = "1",
day = "1",
doi = "10.1016/j.canlet.2015.01.017",
language = "English (US)",
volume = "359",
pages = "233--240",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Defective hCNT1 transport contributes to gemcitabine chemoresistance in ovarian cancer subtypes

T2 - Overcoming transport defects using a nanoparticle approach

AU - Hung, Sau Wai

AU - Marrache, Sean

AU - Cummins, Shannon

AU - Bhutia, Yangzom D.

AU - Mody, Hardik

AU - Hooks, Shelley B.

AU - Dhar, Shanta

AU - Govindarajan, Rajgopal

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Nucleoside analogs are used as chemotherapeutic options for the treatment of platinum-resistant ovarian cancers. Human concentrative nucleoside transporter 1 (hCNT1) is implicated in sensitizing solid tumors to nucleoside analogs although its role in determining drug efficacy in ovarian cancers remains unclear. Here we examined the functional expression of hCNT1 and compared its contributions toward gemcitabine efficacy in histological subtypes of ovarian cancer. Radioactivity analysis identified hCNT1-mediated 3H-gemcitabine transport in ovarian cancer cells to be significantly reduced compared with that of normal ovarian surface epithelial cells. Biochemical and immunocytochemical analysis identified that unlike normal ovarian cells which expressed high levels of hCNT1 at the apical cell surface, the transporter was either diminished in expression and/or mislocalized in cell lines of various subtypes of ovarian cancer. Retroviral expression of hCNT1 selectively rescued gemcitabine transport in cell lines representing serous, teratocarcinoma, and endometrioid subtypes, but not clear cell carcinoma (CCC). In addition, exogenous hCNT1 predominantly accumulated in intracytoplasmic vesicles in CCC suggesting defective cellular trafficking of hCNT1 as a contributing factor to transport deficiency. Despite diminution of hCNT1 transport in the majority of ovarian cancers and apparent trafficking defects with CCC, the chemotherapeutic efficacy of gemcitabine was broadly enhanced in all subtypes when delivered via engineered nanoparticles (NPs). Additionally, by bypassing the transport requirement, the delivery of a gemcitabine-cisplatin combination in NP formulation increased their synergistic interactions. These findings uncover hCNT1 as a putative determinant for nucleoside analog chemoresistance in ovarian cancer and may help rationalize drug selection and delivery strategies for various histological subtypes of ovarian cancer.

AB - Nucleoside analogs are used as chemotherapeutic options for the treatment of platinum-resistant ovarian cancers. Human concentrative nucleoside transporter 1 (hCNT1) is implicated in sensitizing solid tumors to nucleoside analogs although its role in determining drug efficacy in ovarian cancers remains unclear. Here we examined the functional expression of hCNT1 and compared its contributions toward gemcitabine efficacy in histological subtypes of ovarian cancer. Radioactivity analysis identified hCNT1-mediated 3H-gemcitabine transport in ovarian cancer cells to be significantly reduced compared with that of normal ovarian surface epithelial cells. Biochemical and immunocytochemical analysis identified that unlike normal ovarian cells which expressed high levels of hCNT1 at the apical cell surface, the transporter was either diminished in expression and/or mislocalized in cell lines of various subtypes of ovarian cancer. Retroviral expression of hCNT1 selectively rescued gemcitabine transport in cell lines representing serous, teratocarcinoma, and endometrioid subtypes, but not clear cell carcinoma (CCC). In addition, exogenous hCNT1 predominantly accumulated in intracytoplasmic vesicles in CCC suggesting defective cellular trafficking of hCNT1 as a contributing factor to transport deficiency. Despite diminution of hCNT1 transport in the majority of ovarian cancers and apparent trafficking defects with CCC, the chemotherapeutic efficacy of gemcitabine was broadly enhanced in all subtypes when delivered via engineered nanoparticles (NPs). Additionally, by bypassing the transport requirement, the delivery of a gemcitabine-cisplatin combination in NP formulation increased their synergistic interactions. These findings uncover hCNT1 as a putative determinant for nucleoside analog chemoresistance in ovarian cancer and may help rationalize drug selection and delivery strategies for various histological subtypes of ovarian cancer.

KW - Chemoresistance

KW - Gemcitabine

KW - HCNT1

KW - Nanoparticles

KW - Nucleoside transporter

KW - Ovarian cancer

UR - http://www.scopus.com/inward/record.url?scp=84923069007&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923069007&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2015.01.017

DO - 10.1016/j.canlet.2015.01.017

M3 - Article

VL - 359

SP - 233

EP - 240

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

IS - 2

ER -